This study is in progress, not accepting new patients
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jonathan Goldman, MD

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Jonathan Goldman, MD
Hs Clinical Professor, Medicine. Authored (or co-authored) 112 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) Sign up for this study
- ID
- NCT04819100
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 170 study participants
- Last Updated